2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic HSCT recipientsAutologous HSCT recipientsHaematopoietic stem cell transplantation recipientsStem cell transplantation recipientsCOVID-19 diagnosisHSCT recipientsNational Cancer InstituteHigh riskAllogeneic HSCTOverall survivalTransplantation recipientsCOVID-19Cancer InstituteCox proportional hazards modelAggressive treatment measuresSurvival 30 daysObservational cohort studyMarrow Transplant ResearchPoor overall survivalAge 50 yearsOverall survival probabilityPlasma cell disordersMonths of transplantationProportional hazards modelNational Institute
2019
The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)
Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Bacterial AgentsAntimicrobial StewardshipFebrile NeutropeniaFemaleHematopoietic Stem Cell TransplantationHumansMaleMedication Therapy ManagementMethicillin-Resistant Staphylococcus aureusMiddle AgedNoseRetrospective StudiesStaphylococcal InfectionsTime FactorsVancomycinYoung AdultConceptsHematopoietic stem cell transplant recipientsPost-intervention cohortFebrile neutropeniaVancomycin useVancomycin discontinuationStewardship teamRetrospective analysisMultimodal approachStem cell transplant recipientsResistant Gram-positive organismsResistant Gram-positive infectionsAntibiotic stewardship teamDiscontinuation of vancomycinEvidence of pneumoniaPost-implementation cohortPrevious MRSA infectionCell transplant recipientsGram-positive infectionsNasal swab collectionEmpiric vancomycinFN patientsVancomycin ordersVancomycin usageHSCT recipientsTransplant recipientsHLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research In Translational Medicine 2019, 67: 51-55. PMID: 30683577, PMCID: PMC7735254, DOI: 10.1016/j.retram.2019.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAgedCytomegalovirusCytomegalovirus InfectionsFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA-DP AntigensHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesRetrospective StudiesRisk FactorsTransplant RecipientsTransplantation ImmunologyTransplantation, HomologousVirus ActivationYoung AdultConceptsHLA-DPB1 mismatchingCMV reactivationOverall survivalRisk of aGVHDRisk of relapseCMV serostatusHLA-DPIncrease riskAllogeneic hematopoietic stem cell transplantationAllogeneic stem cell transplantHematopoietic stem cell transplantationMD Anderson Cancer CenterGVHD target tissuesHLA-DP mismatchesRecipient CMV serostatusRisk of GVHDStem cell transplantStem cell transplantationHLA-DP moleculesAnderson Cancer CenterGVHD incidenceCumulative incidenceCell transplantMultivariable analysisCancer Center
2018
CAR‐T cell manufacture: snatching victory when defeat is looming
Gowda L, Shah NC. CAR‐T cell manufacture: snatching victory when defeat is looming. Transfusion 2018, 58: 1335-1337. PMID: 29949188, DOI: 10.1111/trf.14760.Peer-Reviewed Original Research